Can lactoferrin prevent neonatal sepsis and necrotizing enterocolitis?

Area of Science:

• Neonatal medicine
• Microbiology
• Immunology

Background:

• Neonatal sepsis and necrotizing enterocolitis cause significant mortality and morbidity despite antimicrobial use.
• Rising antibiotic resistance and inflammation exacerbate poor outcomes in neonates.
• Novel strategies are required to address inflammation and curb antibiotic resistance.

Purpose of the Study:

• To evaluate lactoferrin as a potential therapeutic agent for preventing neonatal sepsis and necrotizing enterocolitis.
• To assess lactoferrin's immunomodulatory and antimicrobial properties in the context of neonatal intestinal diseases.

Main Methods:

• Review of existing literature on lactoferrin's properties.
• Analysis of animal models demonstrating lactoferrin's anti-inflammatory effects in colitis.
• Reference to an ongoing randomized controlled trial investigating lactoferrin for late-onset sepsis prevention in premature neonates.

Main Results:

• Lactoferrin exhibits broad-spectrum antimicrobial and immunomodulatory activities.
• Animal studies indicate lactoferrin reduces inflammatory injury in colitis models.
• Lactoferrin promotes intestinal cell proliferation and differentiation.

Conclusions:

• Lactoferrin is a promising candidate for preventing neonatal sepsis and necrotizing enterocolitis.
• Further research is essential to validate lactoferrin's safety, tolerability, and efficacy in clinical settings.
• Targeting inflammation and antibiotic resistance with agents like lactoferrin is a critical area for neonatal care.